Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.535 USD | +3.97% | +1.71% | -7.82% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 204M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | -93M | EV / Sales 2024 * | - |
Net cash position 2024 * | 121M | Net cash position 2025 * | 258M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.78
x | P/E ratio 2025 * |
-2.15
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.87% |
Latest transcript on Acumen Pharmaceuticals, Inc.
1 day | +1.19% | ||
1 week | +4.62% | ||
Current month | +5.59% | ||
1 month | -12.60% | ||
3 months | +12.58% | ||
6 months | +66.67% | ||
Current year | -11.46% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Jim Doherty
PSD | President | 56 | Jan. 31 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Director/Board Member | 55 | 22-03-31 | |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 3.54 | +4.11% | 61 378 |
24-05-08 | 3.4 | +1.19% | 149,900 |
24-05-07 | 3.36 | -5.62% | 140,393 |
24-05-06 | 3.56 | +2.01% | 177,331 |
24-05-03 | 3.49 | +0.29% | 247,725 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.46% | 204M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- ABOS Stock